{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:23:23Z","timestamp":1790011403242,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40273-017-0590-5","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T06:45:28Z","timestamp":1511765128000},"page":"115-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Usha G.","family":"Mallya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Boklage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Delea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Daniel","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"issue":"6","key":"590_CR1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCULATIONAHA.112.128413","volume":"127","author":"NJ Pagidipati","year":"2013","unstructured":"Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127(6):749\u201356.","journal-title":"Circulation."},{"issue":"4","key":"590_CR2","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38\u2013360.","journal-title":"Circulation"},{"issue":"10","key":"590_CR3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","volume":"104","author":"AR Sharrett","year":"2001","unstructured":"Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2001;104(10):1108\u201313.","journal-title":"Circulation"},{"issue":"2","key":"590_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"590_CR5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley THJ, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med"},{"issue":"25","key":"590_CR6","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"590_CR7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.CIR.67.5.968","volume":"67","author":"HB Hubert","year":"1983","unstructured":"Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968\u201377.","journal-title":"Circulation"},{"issue":"12","key":"590_CR8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","volume":"43","author":"SE Humphries","year":"2006","unstructured":"Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet. 2006;43(12):943\u20139.","journal-title":"J Med Genet"},{"issue":"9602","key":"590_CR9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"Prospective Studies Collaboration","year":"2007","unstructured":"Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829\u201339.","journal-title":"Lancet"},{"issue":"11","key":"590_CR10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.300.11.1343","volume":"300","author":"J Stamler","year":"2008","unstructured":"Stamler J, Wentworth D, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT)\u2014importance then and now. JAMA. 2008;300(11):1343\u20135.","journal-title":"JAMA"},{"issue":"9976","key":"590_CR11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2015","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.","journal-title":"Lancet"},{"issue":"25","key":"590_CR12","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"25 Pt B","key":"590_CR13","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"590_CR14","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"\u017d Reiner","year":"2011","unstructured":"Reiner \u017d, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, et al. ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32(14):1769\u2013818.","journal-title":"Eur Heart J"},{"issue":"3","key":"590_CR15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","volume":"6","author":"JD Cohen","year":"2012","unstructured":"Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208\u201315.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"590_CR16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jacl.2015.03.031","volume":"9","author":"K Gorcyca","year":"2015","unstructured":"Gorcyca K, Khan I, Wadhera R, Klimchak A, Song X, Sanchez R, et al. Prevalence of atherosclerotic cardiovascular disease (ASCVD) and diabetes populations in the United States [abstract]. J Clin Lipidol. 2015;9(3):424.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"590_CR17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacl.2016.06.011","volume":"10","author":"ND Wong","year":"2016","unstructured":"Wong ND, Young D, Zhao Y, Nguyen H, Caballes J, Khan I, et al. Prevalence of the American College of Cardiology\/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011\u20132012. J Clin Lipidol. 2016;10(5):1109\u201318.","journal-title":"J Clin Lipidol"},{"key":"590_CR18","unstructured":"US Food and Drug Administration. Drugs@FDA. Drugs@FDA 2015. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm . Accessed February 15 2017."},{"issue":"20","key":"590_CR19","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891\u2013900.","journal-title":"N Engl J Med"},{"issue":"25","key":"590_CR20","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"9836","key":"590_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29\u201336.","journal-title":"Lancet"},{"issue":"5","key":"590_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"HN Ginsberg","year":"2016","unstructured":"Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160\u00a0mg\/dl or higher. Cardiovasc Drugs Ther. 2016;30(5):473\u201383.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"19","key":"590_CR23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186\u201394.","journal-title":"Eur Heart J"},{"issue":"6","key":"590_CR24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906\u2013915 e13.","journal-title":"Am Heart J."},{"issue":"16","key":"590_CR25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"43","key":"590_CR26","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003.","journal-title":"Eur Heart J"},{"issue":"8","key":"590_CR27","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"H Bays","year":"2015","unstructured":"Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015;100(8):3140\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"590_CR28","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","journal-title":"J Clin Lipidol"},{"key":"590_CR29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","volume":"223","author":"M Farnier","year":"2016","unstructured":"Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol. 2016;223:750\u20137.","journal-title":"Int J Cardiol"},{"issue":"9858","key":"590_CR30","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995\u20132006.","journal-title":"Lancet"},{"issue":"9858","key":"590_CR31","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007\u201317.","journal-title":"Lancet"},{"issue":"23","key":"590_CR32","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497\u2013506.","journal-title":"JAMA"},{"issue":"20","key":"590_CR33","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408\u201317.","journal-title":"Circulation"},{"issue":"16","key":"590_CR34","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20139.","journal-title":"N Engl J Med"},{"issue":"19","key":"590_CR35","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"590_CR36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","volume":"117","author":"A Kiyosue","year":"2016","unstructured":"Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A phase 3 study of evolocumab (AMG 145) in statin-treated japanese patients at high cardiovascular risk. Am J Cardiol. 2016;117(1):40\u20137.","journal-title":"Am J Cardiol"},{"key":"590_CR37","unstructured":"Repatha [package insert]. Thousand Oaks: Amgen Inc; 2015."},{"issue":"1","key":"590_CR38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Committee Writing","year":"2016","unstructured":"Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92\u2013125.","journal-title":"J Am Coll Cardiol"},{"issue":"29","key":"590_CR39","first-page":"2245","volume":"38","author":"U Landmesser","year":"2017","unstructured":"Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, et al. European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38(29):2245\u201355.","journal-title":"Eur Heart J"},{"key":"590_CR40","unstructured":"Tice JA, Ollendorf DA, Cunningham C, Pearson SD, Kazi DS, Coxson PG, et al. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks. Final report. Institute for Clinical and Economic Review; 2015. https:\/\/icerreview.org\/wp-content\/uploads\/2016\/01\/Final-Report-for-Posting-11-24-15-1.pdf . Accessed August 20 2017."},{"issue":"29","key":"590_CR41","first-page":"2256","volume":"38","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J. 2017;38(29):2256\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"590_CR42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health"},{"issue":"1 Suppl A","key":"590_CR43","first-page":"1","volume":"16","author":"FMCP Format Executive Committee","year":"2010","unstructured":"FMCP Format Executive Committee. The AMCP format for formulary submissions version 3.0. J Manag Care Pharm. 2010;16(1 Suppl A):1\u201330.","journal-title":"J Manag Care Pharm"},{"key":"590_CR44","doi-asserted-by":"crossref","unstructured":"Steen DL, Khan I, Song X, Sanchez R, Gorcyca K, Hollenbeak C, et al. Cardiovascular event rates in a high-risk managed care population in the United States [abstract A1647]. J Am Coll Cardiol. 2015;65(10_S).","DOI":"10.1016\/S0735-1097(15)61647-3"},{"issue":"4","key":"590_CR45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.amepre.2006.12.010","volume":"32","author":"MA Allison","year":"2007","unstructured":"Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32(4):328\u201333.","journal-title":"Am J Prev Med"},{"issue":"260","key":"590_CR46","first-page":"1","volume":"10","author":"DL Blackwell","year":"2014","unstructured":"Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for US adults: National Health Interview Survey, 2012. Vital Health Stat. 2014;10(260):1\u2013161.","journal-title":"Vital Health Stat"},{"issue":"3 Suppl","key":"590_CR47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1\u20138.","journal-title":"J Clin Lipidol"},{"key":"590_CR48","unstructured":"US Census Bureau. Annual estimates of the resident population for selected age groups by sex for the United States, states, counties, and Puerto Rico Commonwealth and municipios: April 1, 2010 to July 1, 2013. 2013. http:\/\/factfinder.census.gov\/faces\/tableservices\/jsf\/pages\/productview.xhtml?src=bkmk . Accessed February 15 2017."},{"key":"590_CR49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.18553\/jmcp.2016.22.6.685","volume":"22","author":"I Lin","year":"2016","unstructured":"Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22:685\u201398.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"590_CR50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","volume":"96","author":"MH Davidson","year":"2005","unstructured":"Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556\u201363.","journal-title":"Am J Cardiol"},{"key":"590_CR51","unstructured":"Leerink Partners LLC. MEDACorp survey: use of anti-PCSK9s in hypercholesterolemia 2014. http:\/\/mpi-group.com\/wp-content\/uploads\/2012\/05\/CostofDispensingStudy_GT.pdf . Accessed February 11 2016."},{"key":"590_CR52","unstructured":"Grant Thornton LLP. National cost of dispensing study: final report. Coalition for Community Pharmacy Action; 2007."},{"issue":"11","key":"590_CR53","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s12325-014-0166-0","volume":"31","author":"SS Johnston","year":"2014","unstructured":"Johnston SS, Nguyen H, Felber E, Cappell K, Nelson JK, Chu B-C, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119\u201333.","journal-title":"Adv Ther"},{"key":"590_CR54","unstructured":"Sanofi-aventis US LLC Regeneron Pharmaceuticals Inc. FDA Advisory Committee Briefing Document Praluent (alirocumab) BLA 125559 Endocrinologic and Metabolic Drugs Advisory Committee Metting Date: June 9, 2015. 2015; http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM449867.pdf . Accessed February 15 2017."},{"key":"590_CR55","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med (Epub 17 Mar 2017).","DOI":"10.1056\/NEJMoa1615664"},{"issue":"8","key":"590_CR56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/11584620-000000000-00000","volume":"29","author":"AK O\u2019Sullivan","year":"2011","unstructured":"O\u2019Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29(8):693\u2013704.","journal-title":"Pharmacoeconomics"},{"key":"590_CR57","unstructured":"America\u2019s Health Insurance Plans. Medicare advantage demographics report; 2015. https:\/\/www.ahip.org\/wp-content\/uploads\/2017\/05\/Medigap_Report_5.1.17.pdf . Accessed February 11 2016."},{"key":"590_CR58","unstructured":"US Census Bureau. Table HI01. Health insurance coverage status and type of coverage by selected characteristics: 2013. US Census Bureau; 2014. https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/income-poverty\/cps-hi\/hi-01.2014.html . Accessed February 15 2017."},{"key":"590_CR59","unstructured":"Smith JC, Medalia C. Health Insurance Coverage in the United States: 2014; 2015. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2015\/demo\/p60-253.pdf . Accessed February 11 2016."},{"key":"590_CR60","unstructured":"US Census Bureau Population Division. Table\u00a09. Projections of the Population by Sex and Age for the United States: 2015 to 2060 (NP2014-T9). US Census Bureau; 2014."},{"key":"590_CR61","unstructured":"Medicaid Drug Rebate Program. Medicaid website. 2016 February 5, 2015; https:\/\/www.medicaid.gov\/Medicaid-CHIP-Program-Information\/By-Topics\/Benefits\/Prescription-Drugs\/Medicaid-Drug-Rebate-Program.html . Accessed February 15 2017."},{"key":"590_CR62","unstructured":"The Express Scripts Lab. The 2015 Drug Tend Report. March 2016. http:\/\/lab.express-scripts.com\/lab\/drug-trend-report . Accessed February 15 2017."},{"issue":"7","key":"590_CR63","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743\u201353.","journal-title":"JAMA"},{"issue":"17","key":"590_CR64","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMp1509863","volume":"373","author":"KA Schulman","year":"2015","unstructured":"Schulman KA, Balu S, Reed SD. Specialty pharmaceuticals for hyperlipidemia\u2014impact on insurance premiums [editorial]. N Engl J Med. 2015;373(17):1591\u20133.","journal-title":"N Engl J Med"},{"issue":"5","key":"590_CR65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014;168(5):682\u20139.","journal-title":"Am Heart J"},{"key":"590_CR66","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","volume":"173","author":"MS Sabatine","year":"2016","unstructured":"Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016;173:94\u2013101.","journal-title":"Am Heart J"},{"issue":"3","key":"590_CR67","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacl.2015.03.096","volume":"9","author":"HE Bays","year":"2015","unstructured":"Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, et al. Alirocumab treatment effect on non-HDL-C: pooled analyses of 10 phase 3 trials in the ODYSSEY program [abstract A183]. J Clin Lipidol. 2015;9(3):471.","journal-title":"J Clin Lipidol"},{"key":"590_CR68","volume-title":"Health, United States, 2014: with special feature on adults aged 55\u201364","author":"National Center for Health Statistics","year":"2015","unstructured":"National Center for Health Statistics. Health, United States, 2014: with special feature on adults aged 55\u201364. Hyattsville: National Center for Health Statistics; 2015. https:\/\/www.cdc.gov\/nchs\/data\/hus\/hus14.pdf . Accessed February 11 2016."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0590-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T17:41:29Z","timestamp":1570383689000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0590-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0590-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}